Celltrion Accelerates Development of Novel First-in-Class Therapy for Obesity, Diabetes, and Metabolic Disorders, Aiming for Next-Year IND Submission
Celltrion, a leading South Korean biopharmaceutical company, announced Friday the commencement of primate toxicology studies for CT-G32, its highly anticipated next-generation obesity drug candidate. This pivotal step significantly accelerates the development of a potential first-in-class therapy designed to offer advanced and comprehensive effects for obesity and related metabolic conditions.
These comprehensive toxicology studies are meticulously evaluating CT-G32’s safety and toxicity profile across a cohort of 252 rats and 48 monkeys. The data gathered is crucial for informing optimal dose selection and ensuring robust safety evaluations in subsequent human clinical trials. Celltrion is strategically poised to submit an Investigational New Drug (IND) application for CT-G32 in the first half of the upcoming year, paving the way for clinical development.
Remarkably, preclinical studies have already highlighted CT-G32’s significant advantages, demonstrating superior weight reduction compared to a benchmark candidate at equivalent doses. Crucially, the candidate also showed impressive preservation of lean body mass, a critical factor for healthy and sustainable weight management.
CT-G32 stands out due to its innovative design, engaging with four distinct biological targets. This ‘quadruple-action’ injectable therapy is poised to offer a significant improvement for patients, promising reduced variability in individual responses, extended long-lasting effects, and enhanced overall weight reduction efficacy compared to existing treatments.
Beyond obesity, Celltrion envisions CT-G32 evolving into a comprehensive metabolic platform capable of intricately regulating fat, muscle, and overall energy metabolism. The company is actively exploring its potential as a groundbreaking therapy for diabetes and metabolic dysfunction-associated steatohepatitis (MASH). This ambitious expansion is supported by a strategic partnership with the esteemed Japanese bio-venture, Scohia Pharma.
Further strengthening its pipeline, Celltrion is simultaneously advancing a multi-action oral obesity candidate. Ongoing research focuses on optimizing its stability and bioavailability, with an Investigational New Drug (IND) application projected for submission in the second half of 2028.
A Celltrion official emphasized the strategic importance of CT-G32, stating, “CT-G32 is being developed as a next-generation candidate designed to overcome the limitations of current GLP-1-based therapies, thereby extending Celltrion’s therapeutic impact beyond obesity into a wider spectrum of metabolic diseases.” The official further elaborated on the company’s broader vision: “By leveraging the robust global development and manufacturing capabilities honed through our successful biosimilar business, Celltrion is committed to continuously expanding its innovative pipeline across critical areas such as obesity and antibody-drug conjugates (ADCs), securing formidable mid- to long-term growth engines for the future.”
hwkan
